Rapid Intact Charge Variant Analysis With Coupled icIEF-MS

Eric Carlson, Ph.D.

President and CEO, Protein Metrics Inc.

Erik Gentalen

Chief Technology Officer, Intabio, Inc.

John Teare

VP CMC, Coagulant Therapeutics Corporation

Testing is required to monitor modifications in biopharmaceutical development, from clone selection to manufacturing. However, current testing approaches for intact proteins are time-consuming and don’t provide real-time analytics to drive decision making.

John Teare, VP, Biological Development & Manufacturing at Coagulent Therapeutics, will discuss how his company is using these technologies for some of the most challenging research: coagulation factors for bleeding disorders.